Investigational drug · Phase 3
VAD044 L-Tartrate gelatin
Also called: Engasertib, VAD044
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hereditary Hemorrhagic Telangiectasia, Hereditary Hemorrhagic Telangiectasia (HHT).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
1
Any phase or sponsor naming "VAD044 L-Tartrate gelatin"
First trial start
2022
Jul 18, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VAD044 L-Tartrate gelatin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hereditary Hemorrhagic Telangiectasia
- Hereditary Hemorrhagic Telangiectasia (HHT)
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "VAD044 L-Tartrate gelatin" as an intervention, largest first.
- Assess Safety and Efficacy of VAD044 in HHT PatientsActive, not recruiting
Vaderis Therapeutics AGIndustry
NCT05406362 · 75 participants · Start Jul 18, 2022 · Primary completion Jan 2027
Drug: VAD044 Part I; VAD044 Part II · For: Hereditary Hemorrhagic Telangiectasia (HHT)
Sites: Boston, Massachusetts; Ghent, Belgium; Lyon, France · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging novel therapies for the treatment of hereditary haemorrhagic telangiectasia.
Al-Samkari H · Lancet Haematol 2026
- Engasertib in Hereditary Hemorrhagic Telangiectasia. Reply.
Al-Samkari H, Picard D, Mager HJ · N Engl J Med 2026
- Engasertib in Hereditary Hemorrhagic Telangiectasia.
Liang D, Lin Y, He L · N Engl J Med 2026
- Engasertib versus Placebo for Bleeding in Hereditary Hemorrhagic Telangiectasia.
Al-Samkari H, Hessels J, Riera-Mestre A, et al. · N Engl J Med 2025
Also in development for Hereditary Hemorrhagic Telangiectasia
- ALN-6400Phase 22 trials
Alnylam Pharmaceuticals · Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB), Hereditary Hemorrhagic Telangiectasia
- DIAG723Phase 21 trial
Diagonal Therapeutics, Inc. · Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.